Table 7 Studies of stereotactic body radiotherapy for stage I NSCLC in the elderly
Author | Age (range) | n | T stage | Doses | Local control | Overall survival |
|---|---|---|---|---|---|---|
Haasbeek CJ et al. [9] | ≥ 75 (75–91) | 193 | T1 118 | 60 Gy/3 fr | 89% at 3 years | 45% at 3 years |
T2 85 | 60 Gy/5 fr | |||||
60 Gy/8 fr | ||||||
Takeda A et al. [12] | ≥ 80 (80–91) | 109 | T1a 32 | 50 Gy/4 fr | 82.3% at 3 years | 53.7% at 3 years |
T1b 35 | 40 Gy/ 5 fr | |||||
T2 42 | ||||||
Sandhu AP et al. [11] | ≥ 80 (80–89) | 24 | T1 18 | 48 Gy/4 fr | 100% | 74% at 2 years |
T2a 6 | 56 Gy/5 fr | (4.3–61.2 months) | ||||
This study | ≥ 85 (85–93) | 20 | T1a 9 | 48 Gy/4 fr | 83.1% at 3 years | 71.2% at 2 years |
(Hayashi S et al.) | T1b 7 | 60 Gy/10 fr | 40.7% at 3 years | |||
T2a 4 |